Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Discovery Fund Randy Gwirtzman | “Inspire Medical Systems, Inc. is a medical device company offering a treatment option called hypoglossal nerve stimulation for patients with moderate-to-severe obstructive sleep apnea. Shares fell during the quarter as management lowered 2025 financial guidance, citing several factors behind the slower-than-expected rollout of Inspire 5, the company's next-generation device. These included delays onboarding centers to a new patient management platform, a postponed Medicare reimbursement code that did not take effect until July 1 due to a software update, patients deferring procedures in anticipation of Inspire 5's availability, and management's decision to pause marketing efforts and new center expansion. In addition, management noted anecdotal reports of some patients delaying procedures to try GLP-1 medications. We exited our position. BSD Analysis: The thesis hinges on execution: guidance cuts, implementation frictions, and possible demand deferral versus GLP-1 use undermine near-term growth visibility and multiple support. Reimbursement and center productivity are key KPIs; until adoption of Inspire 5 stabilizes, downside risk to revenue growth and gross margin exists. Given decelerating momentum and competitive obesity therapies, we agree with the manager's bearish stance and exit decision. Watch for clearer procedure trends and center ramp data before reconsidering. :contentReference[oaicite:2]{index=2}” | BEAR | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
